Should You Buy Cytosorbents Corporation Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Cytosorbents Corporation (CTSO) presents a moderate quality profile with a QOC score of 5.2/10. Trading at $6.06, separating genuine undervalued opportunities from value traps is essential, as detailed by our model data.
The short answer: 1 of 2 CirclFi valuation models project upside for Cytosorbents Corporation (CTSO) at $6.06 — the models are evenly split, with a Quality Score of 5.2/10 and Value-Trap risk of 26/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Cytosorbents Corporation (CTSO) in 2026?
What Is the Bull Case vs the Bear Case for Cytosorbents Corporation (CTSO)?
| Bull case — $9.24 target (+52.4%) | Bear case — $2.53 target (-58.3%) |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, the PWERM model targets a fair value of $9.24 (+52.4%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Quality of Company (QOC) framework, Cytosorbents Corporation's rating of 5.2/10 indicates below-average quality, raising questions about sustainable earnings levels. |
| Industry tailwind: regulatory pathway clarity could provide meaningful support for Cytosorbents Corporation's revenue and margin trajectory in the Medical Devices space. | According to the CirclFi Deep Alpha Valuation Engine, the Dynamic NAV model sees the stock as overvalued with a fair value of $2.53 (-58.3%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +110.7% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. | |
| Industry headwind: clinical trial failure represents a meaningful risk for Cytosorbents Corporation and its Medical Devices peers. |
How Does CTSO Compare to Its Medical Devices Peers?
Valuation data pages: ELUT · CATX · IRIX · MDAI · NUWE · IVF · IRMD · AORT · CVRX · PODD
Which Other Stocks Score Like CTSO on Quality?
Closest companies to CTSO’s Quality of Company score of 5.2/10, across all industries.
- CNET — ZW Data Action Technologies Inc. (QOC 5.2) · analysis
- STNE — StoneCo Ltd. (QOC 5.2) · analysis
- FLNT — Fluent, Inc. (QOC 5.2) · analysis
- TUSK — Mammoth Energy Services, Inc. (QOC 5.2) · analysis
- NAAS — NaaS Technology Inc. (QOC 5.2) · analysis
- DAIC — CID HoldCo, Inc. (QOC 5.2) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Medical Devices Screens Does CTSO Appear In?
So Is Cytosorbents Corporation (CTSO) Worth Buying in 2026?
Our models don't have a clear verdict on Cytosorbents Corporation. At $6.06 vs. $5.88 median fair value, the median upside of -2.9% masks significant model disagreement (+110.7% spread). With quality at 5.2/10, this is a stock where the margin of error is wide and additional fundamental research is strongly recommended.
These are quantitative model outputs, not investment recommendations. Cytosorbents Corporation's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About CTSO Stock?
Should I buy CTSO stock right now?
Based on CirclFi's multi-model analysis, 1 of 2 models see upside for CTSO at $6.06. The models are divided, which means the investment case depends heavily on your assumptions about Cytosorbents Corporation's future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Cytosorbents Corporation?
Key risks include: limited model coverage (2/13 active), reducing analytical confidence; wide model disagreement (265% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Devices companies. Always diversify and consult a financial advisor.
How does CTSO compare to its competitors?
Among Medical Devices peers, CTSO holds a Quality Score of 5.2/10. Comparable companies include ELUT (QOC 5.2), CATX (QOC 5.2), IRIX (QOC 5.2). The relative ranking helps investors identify whether CTSO offers better fundamental quality than alternatives in the same sector.
Is CTSO a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. CTSO's Quality Score of 5.2/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy CTSO at?
CirclFi does not provide target buy prices or price alerts. However, our 2 active models produce fair value estimates ranging from $2.53 to $9.24. At $6.06, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for CTSO.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad